Accelerate successful drug development

Proteomics in drug development

Incomplete knowledge of the real-time biology underlying disease and drug action can drive up costs and time in drug development. Protein biomarkers, along with other omics markers, can be used to predict response, stratify patient populations, and provide insights into the biology of disease.

Olink offers a high-throughput solution for protein biomarker discovery with thousands of thoroughly validated assays that provide exceptional specificity at high-multiplex levels and has been widely used in clinical biomarker research. It can be applied across all stages of drug development, from early discovery through preclinical and clinical development to post-approval activities such as post-market surveillance and label expansion.

Key applications to address the major challenges of drug development

Escalating costs and increasing demands from regulatory authorities for a more precision medicine-based approach to drug development are substantial challenges for the pharmaceutical industry. Faster drug discovery with increased probability of successful implementation of new therapies can be greatly facilitated by multiomics approaches that can enable deep knowledge of the biology underlying human disease and provide actionable insights to accelerate key decision making. Proteomics is now taking center stage in these approaches, and Olink’s proximity extension assay (PEA) technology is increasingly used in key applications that can accelerate successful drug development.

Pharma-led proteomics initiatives

The importance of proteomics for future drug development is exemplified in the UK Biobank Pharma Proteomics Project (UKB-PPP), where a consortium of 13 leading pharma companies funded a project to measure ~1500 proteins in over 53,000 individuals with the goal of better understanding of disease biology and more effective therapies. Recently published early findings reported over 10,000 primary genetic associations with plasma protein levels (pQTLs), 85% of which are novel findings. Read more about this and other collaborative initiatives aimed towards future drug development in our blog post.

Proteomics to accelerate successful drug development - key applications

Identify protein biomarkers that are causal for diseases

Save time/cost/inconvenience of invasive sampling (tissue biopsies, imaging etc)

Reduce the size and cost of clinical trials by identifying likely responders during selection of enrollees

Characterize mode of drug action through deep understanding of disease biology

Successful application of drugs to the right patients

New applications through deeper understanding of disease patho-mechanisms

Proteomics & multiomic studies will revolutionize future drug development

Proteomics at the heart of multiomics strategies

Systems biology approaches addressing multiple molecular and cellular components are adding vital insights into the dynamic biology underlying human health and disease.

Hear from industry experts on how proteomics is changing the way we develop new drugs and study disease.

The power of proteomics in multiomic studies

Download the eBook, ‘Proteomics at the heart of multiomic studies’ to learn more about how this trend is the next step in advancing precision medicine.

Want to know more?

2947

Biomarker assays

~881 million

Protein data points generated

1068

Publications listed on website

Contact us!